Medicare AdvantageFebruary 27, 2025
Clinical Criteria updates
Effective March 28, 2025
Summary: The Pharmacy and Therapeutics (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for BMA. These policies were developed, revised, or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.
Please see the explanation/definition for each category of Clinical Criteria below:
- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
Please share this notice with other members of your practice and office staff.
Please note:
- The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical plan. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by BMA only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective Date | Clinical Criteria Number | Clinical Criteria Title | New or Revised |
March 28, 2025 | CC-0274 | Bizengri (zenocutuzumab-zbco) | New |
March 28, 2025 | CC-0275 | Ziihera (zanidatamab-hrii) | New |
March 28, 2025 | CC-0276 | Tryngolza (olezarsen) | New |
March 28, 2025 | CC-0072 | Vascular Endothelial Growth Factor (VEGF) Inhibitors | Revised |
March 28, 2025 | CC-0185 | Oxlumo (lumasiran) | Revised |
March 28, 2025 | CC-0198 | Relizorb (immobilized lipase) cartridge | Revised |
March 28, 2025 | CC-0256 | Rivfloza (nedosiran) | Revised |
March 28, 2025 | CC-0042 | Monoclonal Antibodies to Interleukin-17 | Revised |
March 28, 2025 | CC-0063 | Ustekinumab Agents (Stelara, Selarsdi, Imuldosa, Pyzchiva, Otulfi, Wezlana, Yesintek) | Revised |
March 28, 2025 | CC-0058 | Bynfezia Pen, Sandostatin, or Sandostatin LAR (Octreotide) / Octreotide Agents | Revised |
March 28, 2025 | CC-0130 | Imfinzi (durvalumab) | Revised |
March 28, 2025 | CC-0094 | Pemetrexed | Revised |
March 28, 2025 | CC-0003 | Immunoglobulins | Revised |
Blue Medicare Advantage is the trade name of Group Retiree Health Solutions, Inc., an independent licensee of the Blue Cross Blue Shield Association.
PAIBC-CR-077234-25-CPN76946
To view this article online:
Visit https://providernews.anthem.com/pennsylvania/articles/clinical-criteria-updates-24342
Or scan this QR code with your phone